Robert T. Dorr - Publications

University of Arizona, Tucson, AZ 
Pharmaceutical Chemistry, Nutrition, Pharmacology

71 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biology & Therapy. 16: 43-51. PMID 25485960 DOI: 10.4161/15384047.2014.986967  0.32
2015 Samulitis Bk, Pond E, Pond K, Cress AE, Dorr RT, Landowski TH. Abstract B42: Adaptive drug resistance is associated with phenotypic reprogramming and hypersensitivity to HDAC inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B42  0.32
2015 Remers WA, Iyengar BS, Dorr RT, Wisner L, Bates RB. Synthesis and antitumor activity of heterocycles related to carbendazim Journal of Heterocyclic Chemistry. 52: 136-141. DOI: 10.1002/Jhet.1976  0.48
2014 Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, ... ... Dorr RT, et al. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 124: 1259-65. PMID 25016003 DOI: 10.1182/Blood-2014-04-570044  0.48
2013 Landowski TH, Samulitis BK, Dorr RT. The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investigational New Drugs. 31: 1616-25. PMID 24037082 DOI: 10.1007/S10637-013-0019-8  0.32
2013 Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 71: 1567-76. PMID 23572175 DOI: 10.1007/S00280-013-2156-3  0.48
2013 Dorr RT, Samulitis BK, Wisner L, Han H, Zhao Y, Beroza P, Damodaran K, Igarashi S, Landowski TH, Von Hoff DD. Characterization of a membrane-active anti-tumor agent, UA8967 Investigational New Drugs. 31: 576-586. PMID 23179338 DOI: 10.1007/S10637-012-9901-Z  0.48
2012 Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Translational Oncology. 5: 190-9. PMID 22741038 DOI: 10.1593/Tlo.11322  0.48
2012 Tome ME, Frye JB, Coyle DL, Jacobson EL, Samulitis BK, Dvorak K, Dorr RT, Briehl MM. Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. Experimental and Therapeutic Medicine. 3: 845-852. PMID 22529877 DOI: 10.3892/Etm.2012.487  0.48
2012 Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Molecular Cancer Research : McR. 10: 392-400. PMID 22275514 DOI: 10.1158/1541-7786.Mcr-11-0359  0.32
2012 Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemotherapy and Pharmacology. 69: 1039-49. PMID 22186884 DOI: 10.1007/S00280-011-1784-8  0.32
2012 Samulitis B, Wisner L, Dorr R, Landowski TH. Abstract 797: Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with characteristics of EMT Cancer Research. 72: 797-797. DOI: 10.1158/1538-7445.Am2012-797  0.36
2011 Samulitis BK, Dorr RT, Chow HH. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. Anticancer Research. 31: 2781-5. PMID 21868520  0.32
2011 Roman NO, Samulitis BK, Wisner L, Landowski TH, Dorr RT. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology. 67: 183-92. PMID 20339847 DOI: 10.1007/S00280-010-1306-0  0.48
2011 Dorr RT, Wisner L, Samulitis B, Landowski TH, Remers WA. Abstract 671: Tumor delay and mechanism of action studies of a novel cyanoaziridine derivative, AMP423 Cancer Research. 71: 671-671. DOI: 10.1158/1538-7445.Am2011-671  0.36
2010 Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 116: 3683-91. PMID 20564083 DOI: 10.1002/Cncr.25119  0.32
2010 Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66: 287-94. PMID 19855966 DOI: 10.1007/S00280-009-1162-Y  0.48
2010 Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase i trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer Investigational New Drugs. 28: 634-640. PMID 19499186 DOI: 10.1007/S10637-009-9273-1  0.48
2009 Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. The Journal of Pharmacology and Experimental Therapeutics. 331: 636-47. PMID 19657049 DOI: 10.1124/Jpet.109.156406  0.48
2009 Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT. Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorganic & Medicinal Chemistry Letters. 19: 4752-5. PMID 19615898 DOI: 10.1016/J.Bmcl.2009.06.063  0.52
2009 Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD. UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics. 8: 36-44. PMID 19139111 DOI: 10.1158/1535-7163.Mct-08-0789  0.48
2009 Samulitis BK, Landowski TH, Dorr RT. Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Investigational New Drugs. 27: 89-98. PMID 18607542 DOI: 10.1007/S10637-008-9149-9  0.32
2008 Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, Alberts DS. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutrition and Cancer. 60: 325-30. PMID 18444166 DOI: 10.1080/01635580701840391  0.48
2008 Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochemical Pharmacology. 75: 883-90. PMID 18062937 DOI: 10.1016/J.Bcp.2007.10.026  0.48
2007 Pawar SC, Dougherty S, Pennington ME, Demetriou MC, Stea BD, Dorr RT, Cress AE. alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation. International Journal of Radiation Biology. 83: 761-7. PMID 18058365 DOI: 10.1080/09553000701633135  0.48
2007 Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3388-94. PMID 17545547 DOI: 10.1158/1078-0432.Ccr-06-0873  0.4
2007 Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow H-S, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R. Phase I Trial of Imexon in Patients With Advanced Malignancy Journal of Clinical Oncology. 25: 1779-1784. PMID 17470869 DOI: 10.1200/Jco.2006.08.9672  0.36
2007 Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 1109-17. PMID 17351106 DOI: 10.1124/Jpet.106.117457  0.44
2007 Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemotherapy and Pharmacology. 59: 749-57. PMID 17333195 DOI: 10.1007/S00280-006-0329-Z  0.36
2007 Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Investigational New Drugs. 25: 107-14. PMID 17024575 DOI: 10.1007/S10637-006-9015-6  0.52
2006 Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-Cancer Drugs. 17: 1179-84. PMID 17075317 DOI: 10.1097/01.Cad.0000236305.43209.F0  0.52
2006 Tome ME, Johnson DB, Samulitis BK, Dorr RT, Briehl MM. Glucose 6-phosphate dehydrogenase overexpression models glucose deprivation and sensitizes lymphoma cells to apoptosis. Antioxidants & Redox Signaling. 8: 1315-27. PMID 16910779 DOI: 10.1089/Ars.2006.8.1315  0.48
2006 Samulitis BK, Landowski TH, Dorr RT. Correlates of imexon sensitivity in human multiple myeloma cell lines. Leukemia & Lymphoma. 47: 97-109. PMID 16321833 DOI: 10.1080/10428190500266210  0.32
2006 Dragovich T, Mendelson M, Modiano M, Gordon M, Grenier K, Dorr R, Hersh E. 432 POSTER Phase I study of Amplimexon™ (imexon, inj.) in patients with advanced solid tumors and lymphomas: final report Ejc Supplements. 4: 132. DOI: 10.1016/S1359-6349(06)70437-2  0.32
2005 Dragovich T, Mendelson D, Gordon M, Long K, Downhour M, Dorr R, Hersh E. Phase I trial of imexon (IMX) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3153. PMID 27946194 DOI: 10.1200/Jco.2005.23.16_Suppl.3153  0.32
2005 Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. International Journal of Gastrointestinal Cancer. 36: 15-28. PMID 16227632 DOI: 10.1385/Ijgc:36:1:015  0.48
2005 Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Research. 65: 3828-36. PMID 15867381 DOI: 10.1158/0008-5472.Can-04-3684  0.48
2005 Lambert JD, Sang S, Dougherty A, Caldwell CG, Meyers RO, Dorr RT, Timmermann BN. Cytotoxic lignans from Larrea tridentata. Phytochemistry. 66: 811-5. PMID 15797607 DOI: 10.1016/J.Phytochem.2005.02.007  0.52
2005 Jagadish B, Iyengar BS, Sólyom AM, Remers WA, Dorr RT, Yu JS, Gupta S, Mash EA. Synthesis of [14C]-imexon Journal of Labelled Compounds and Radiopharmaceuticals. 48: 165-170. DOI: 10.1002/Jlcr.911  0.48
2004 Dorr RT, Dragovich T, Hersh E, Patrick K. Phase I clinical trial of imexon: A mitochondrial thiol oxidant. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3181. PMID 28014914 DOI: 10.1200/Jco.2004.22.14_Suppl.3181  0.32
2004 Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology. 140: 827-35. PMID 15262693 DOI: 10.1001/Archderm.140.7.827  0.4
2003 Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3312-9. PMID 12960117  0.48
2003 Horais K, Hruby V, Rossi S, Cizkova D, Meschter C, Dorr R, Yaksh TL. Effects of chronic intrathecal infusion of a partial differential opioid agonist in dogs. Toxicological Sciences : An Official Journal of the Society of Toxicology. 71: 263-75. PMID 12563112 DOI: 10.1093/Toxsci/71.2.263  0.48
2002 Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, Coon A, Dorr RT. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Molecular Cancer Therapeutics. 1: 185-95. PMID 12467213  0.48
2002 Lambert JD, Zhao D, Meyers RO, Kuester RK, Timmermann BN, Dorr RT. Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon : Official Journal of the International Society On Toxinology. 40: 1701-8. PMID 12457882 DOI: 10.1016/S0041-0101(02)00203-9  0.48
2002 Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anti-Cancer Drugs. 13: 1031-42. PMID 12439337 DOI: 10.1097/00001813-200211000-00007  0.48
2001 Waltmire CN, Alberts DS, Dorr RT. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. Anti-Cancer Drugs. 12: 595-602. PMID 11487716 DOI: 10.1097/00001813-200108000-00006  0.32
2001 Lambert JD, Meyers RO, Timmermann BN, Dorr RT. tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Letters. 171: 47-56. PMID 11485827 DOI: 10.1016/S0304-3835(01)00560-2  0.52
2001 Zhou Q, Duan W, Simmons D, Shayo Y, Raymond MA, Dorr RT, Hurley LH. Design and synthesis of a novel DNA-DNA interstrand adenine-guanine cross-linking agent. Journal of the American Chemical Society. 123: 4865-6. PMID 11457309 DOI: 10.1021/Ja005658R  0.48
2001 Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood. 97: 3544-51. PMID 11369649 DOI: 10.1182/Blood.V97.11.3544  0.48
2001 Lambert JD, Meyers RO, Timmermann BN, Dorr RT. Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. Journal of Chromatography. B, Biomedical Sciences and Applications. 754: 85-90. PMID 11318430 DOI: 10.1016/S0378-4347(00)00592-2  0.52
2001 Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1589-99. PMID 11250987 DOI: 10.1200/Jco.2001.19.6.1589  0.48
2000 Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 72: 526-32. PMID 11045725 DOI: 10.1562/0031-8655(2000)072<0526:Ieeati>2.0.Co;2  0.48
2000 Stratton SP, Bangert JL, Alberts DS, Dorr RT. Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice. Cancer Letters. 158: 47-52. PMID 10940508 DOI: 10.1016/S0304-3835(00)00498-5  0.4
2000 Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochemical Pharmacology. 60: 749-58. PMID 10930529 DOI: 10.1016/S0006-2952(00)00380-4  0.48
2000 Bhardwaj R, Hadley ME, Dorr RT, Dvorakova K, Brooks C, Blanchard J. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I. Pharmaceutical Research. 17: 593-9. PMID 10888312 DOI: 10.1023/A:1007525117894  0.48
2000 Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. European Journal of Cancer (Oxford, England : 1990). 36: 1292-7. PMID 10882869 DOI: 10.1016/S0959-8049(00)00108-8  0.4
2000 Monsky WL, Heddens DK, Clark GM, Von Hoff DD, Coltman CA, Dorr RT, Alberts DS. Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 437-44. PMID 10637260 DOI: 10.1200/Jco.2000.18.2.437  0.36
1999 Dvorakova K, Dorr RT, Valcic S, Timmermann B, Alberts DS. Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemotherapy and Pharmacology. 43: 331-5. PMID 10071985 DOI: 10.1007/S002800050903  0.48
1997 Dvorakova K, Dorr RT, Gallegos A, McClure T, Powis G. Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 275-81. PMID 9323548 DOI: 10.1016/S0378-4347(97)00261-2  0.48
1997 Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemotherapy and Pharmacology. 40: 209-14. PMID 9219503 DOI: 10.1007/S002800050648  0.48
1996 Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Investigational New Drugs. 14: 131-7. PMID 8913833 DOI: 10.1007/Bf00210783  0.48
1995 Surendran N, Ugwu SO, Nguyen LD, Sterling EJ, Dorr RT, Blanchard J. Absorption enhancement of melanotan-l: Comparison of the caco-2 and rat in situ models Drug Delivery. 2: 49-55. DOI: 10.3109/10717549509031351  0.48
1994 Parrish AR, Dorr RT, Gandolfi AJ, Brendel K. Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity. Toxicology in Vitro : An International Journal Published in Association With Bibra. 8: 1233-7. PMID 20693093 DOI: 10.1016/0887-2333(94)90114-7  0.48
1993 List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1652-60. PMID 8102639 DOI: 10.1200/Jco.1993.11.9.1652  0.48
1991 Elam EA, Dorr RT, Lagel KE, Pond GD. Cutaneous ulceration due to contrast extravasation. Experimental assessment of injury and potential antidotes. Investigative Radiology. 26: 13-6. PMID 2022447 DOI: 10.1097/00004424-199101000-00003  0.48
1991 Alberts DS, Mason-liddil N, Plezia PM, Roe DJ, Dorr RT, Struck RF, Phillips JG. Lack of ranitidine effects on cyclophosphamide bon marrow toxicity or metabolism: A placebo-controlled clinical trial Journal of the National Cancer Institute. 83: 1739-1743. PMID 1770553 DOI: 10.1093/Jnci/83.23.1739  0.48
1987 Phelps JS, Gandolfi AJ, Brendel K, Dorr RT. Cisplatin nephrotoxicity: In vitro studies with precision-cut rabbit renal cortical slices Toxicology and Applied Pharmacology. 90: 501-512. PMID 3310337 DOI: 10.1016/0041-008X(87)90142-6  0.48
1987 Dorr RT, Liddil JD, Trent JM, Dalton WS. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochemical Pharmacology. 36: 3115-20. PMID 3117061 DOI: 10.1016/0006-2952(87)90620-4  0.48
1979 Dorr RT, Jones SE. Inapparent infiltrations associated with vindesine administration Medical and Pediatric Oncology. 6: 285-288. PMID 481319 DOI: 10.1002/Mpo.2950060403  0.48
1979 Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy New England Journal of Medicine. 300: 1295-1297. PMID 375088 DOI: 10.1056/Nejm197906073002302  0.48
Show low-probability matches.